MedTrace Logo

Ambroxol to Slow Progression in Parkinson Disease

NCT05778617 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2025-05-01

No results posted yet for this study

Summary

This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to evaluate it's safety and tolerability.

Conditions

  • Parkinson Disease

Interventions

DRUG

Ambroxol Hydrochloride (420mg)

Oral tablet

DRUG

Placebo

Oral tablet

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Anthony Schapira · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-25
Primary Completion
2029-02-28
Completion
2029-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05778617 on ClinicalTrials.gov